SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001140361-18-022477
Filing Date
2018-05-09
Accepted
2018-05-09 16:01:22
Documents
2
Period of Report
2018-05-07

Document Format Files

Seq Description Document Type Size
1 FORM 4 form4.html 4  
1 FORM 4 form4.xml 4 6883
2 EXHIBIT 24 - POWER OF ATTORNEY ex24.htm EX-24 5949
  Complete submission text file 0001140361-18-022477.txt   15085
Mailing Address LICHTSTRASSE 35 BASEL V8 CH 4056
Business Address LICHTSTRASSE 35 BASEL V8 CH 4056 01141613241111
NOVARTIS AG (Reporting) CIK: 0001114448 (see all company filings)

State of Incorp.: V8 | Fiscal Year End: 1231
Type: 4 | Act: 34 | File No.: 001-37722 | Film No.: 18818178
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O NOVARTIS INTERNATIONAL AG WSJ-200.220 CH-4002 BASEL V8 0000000000
Business Address C/O NOVARTIS INTERNATIONAL AG WSJ-200.220 CH-4002 BASEL V8 0000000000 41-61-324-6210
Novartis Bioventures Ltd (Reporting) CIK: 0001297709 (see all company filings)

State of Incorp.: D0 | Fiscal Year End: 1231
Type: 4 | Act: 34 | File No.: 001-37722 | Film No.: 18818179

Mailing Address 901 S. MOPAC EXPRESSWAY, STE. 250 BARTON OAKS PLAZA ONE AUSTIN TX 78746
Business Address 901 S. MOPAC EXPRESSWAY, STE. 250 BARTON OAKS PLAZA ONE AUSTIN TX 78746 (512) 942-2935
Aeglea BioTherapeutics, Inc. (Issuer) CIK: 0001636282 (see all company filings)

IRS No.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations